湖北亨迪药业股份有限公司2025年年度报告详细解读

一、报告要点综述

• 公司2025年实现营业收入4.53亿元，同比增长1.67%。
• 归属于上市公司股东的净利润为3491万元，同比大幅下降61.87%。
• 制剂销售收入突破亿元大关，达到1.07亿元，同比增长26.11%。
• 公司继续推进“原料药+制剂”一体化战略，制剂新产品陆续获批上市。
• 公司研发投入2879万元，同比下降12.58%，但多个新药品种取得注册证书或顺利推进。
• 公司再次获得高新技术企业认定，持续强化创新能力。
• 布洛芬原料药重排水解酸化岗位安全环保升级技改项目已正式投用，高端医药制剂国际化项目启动土建施工。
• 现金流表现显著下滑，经营活动现金流净额仅为755万元，同比下降92.14%。
• 公司申报两项新专利，目前均已进入实质审查阶段。
• 全资子公司武汉百科药物通过美国FDA cGMP现场检查，彰显国际化质量管理水平。
• 利润分配方案：每10股派发现金红利0.6元（含税）。

二、对投资者和股东的关键影响

• 利润大幅下滑：归属于上市公司股东的净利润同比下降超过60%，扣除非经常性损益的净利润下降近90%，反映公司主营业务盈利压力加大，需重点关注后续盈利能力恢复。
• 现金流骤降：经营活动现金流量净额同比减少逾9成，显示公司运营资金压力明显上升，可能影响分红及未来扩张。
• 制剂销售持续增长：公司制剂业务表现抢眼，销售收入同比增长26.11%，战略转型效果初显。
• 研发进展：虽然研发投入有所下降，但多个新药品种取得注册证书，包括布洛芬缓释胶囊、托拉塞米注射液、布洛芬混悬液和非布司他片，未来新产品上市有望贡献增量。
• 专利与国际认证：新专利申报及美国FDA cGMP认证提升公司技术壁垒和国际竞争力。
• 高新技术企业认定：再次获认定，利于税收优惠政策持续享受。
• 募投项目进展：布洛芬原料药安全环保升级技改项目已正式投用，高端制剂国际化项目已取得施工许可证，未来产能及市场拓展值得期待。
• 分红方案：每10股派发现金红利0.6元，显示公司仍重视股东回报。
• 股权结构稳定：控股股东和实际控制人未发生变化，部分股东股份存在质押情况，需关注质押风险。

三、公司主营产品及市场优势

• 原料药业务：公司以非甾体抗炎类原料药为核心，心血管、抗肿瘤、抗胆碱类原料药为辅助，产品符合中国、美国、欧洲药典及GMP认证，全球80多个国家注册，成为多家世界医药巨头的合格供应商。
• 制剂业务：以自产原料药为基础，开发解热镇痛类、心血管类、抗感染类等制剂，部分产品进入国家医保及基药目录，市场前景广阔。
• CDMO业务：提供从临床前到商业化阶段的研发、生产、注册申报等一站式服务，打造行业领先的合同研发生产能力。
• 主要产品：布洛芬、右旋布洛芬、托拉塞米、米力农、醋酸阿比特龙、磷酸氟达拉滨、盐酸格拉司琼、克拉屈滨、硫酸莨菪碱、硫酸阿托品等，制剂如布洛芬颗粒/缓释胶囊/混悬液、托拉塞米片等。
• 新药研发：报告期内新药如布洛芬缓释胶囊、托拉塞米注射液、布洛芬混悬液、非布司他片等取得注册证书，精氨酸布洛芬原料药和甲氧氯普胺原料药获批上市，其他品种在研。

四、财务数据与股东结构

• 资产规模：总资产24.89亿元，同比下降3.49%。
• 净资产：归属于上市公司股东的净资产23.10亿元，同比下降1.58%。
• 每股收益：基本每股收益0.08元，较去年大幅下降。
• 股东结构：控股股东上海勇达圣商务咨询有限公司持股38.25%，实际控制人刘益谦子女形成一致行动关系，部分股东股份存在质押。
• 债务情况：公司当前无存续债券。
• 季度表现：四季度净利润恢复明显，全年主要利润来源于四季度。

五、投资风险与潜在影响

• 盈利能力波动大：净利润和扣非净利润大幅下滑，需警惕未来业绩不确定性。
• 现金流风险：经营现金流大幅下滑，可能影响分红及项目投入。
• 股权质押：部分主要股东股份存在质押，需关注潜在平仓风险。
• 新产品上市：新药品种陆续获批上市，若市场表现优异，将成为业绩增长新动力。
• 国际市场拓展：CDMO和原料药国际化项目推进，若能顺利放量，将显著提升公司估值。
• 分红方案：维持现金分红，显示公司现金流仍可支持股东回报。
• 高新技术企业认定：有助于税收优惠及政策支持。

六、结论与展望

湖北亨迪药业2025年年度报告显示，公司正处于战略转型与新产品布局关键期。虽然盈利和现金流压力较大，但制剂业务成长、国际认证、专利布局和募投项目进展为未来打开增长空间。新药品种上市、国际市场拓展有望成为业绩反转的关键驱动力。投资者需密切关注公司后续经营恢复、创新成果转化、现金流状况及股权质押风险，短期内市场情绪可能受净利润下滑及现金流压力影响，长期看公司如能实现制剂业务和国际化突破，将显著提升估值。

免责声明

本文仅为信息披露解读，不构成投资建议。投资者应结合自身风险承受能力，关注公司公告及市场变化，理性决策。

Hubei Hengdi Pharmaceutical Co., Ltd. 2025 Annual Report Detailed Analysis (English)

• 2025 revenue reached RMB 453 million, up 1.67% YoY.
• Net profit attributable to shareholders was RMB 34.91 million, down 61.87% YoY.
• Formulation sales exceeded RMB 100 million, up 26.11% YoY.
• Integrated strategy of “API + Formulation” progressing, new formulation products approved for market.
• R&D investment was RMB 28.79 million, down 12.58%, but several key new drugs obtained registration certificates or made progress.
• Company regained High-Tech Enterprise certification, reinforcing innovation capabilities.
• Ibuprofen API safety/environmental upgrade project officially put into use; international high-end formulation project construction started.
• Cash flow sharply declined: net cash from operations only RMB 7.55 million, down 92.14% YoY.
• Two new patents filed, now under substantive examination.
• Wholly-owned subsidiary Wuhan Baike Pharmaceutical passed US FDA cGMP inspection, highlighting international quality standards.
• Dividend plan: cash dividend of RMB 0.6 per 10 shares (pre-tax).

Key Impacts for Investors and Shareholders

• Sharp Profit Decline: Net profit attributable to shareholders fell over 60%, and net profit excluding non-recurring items dropped nearly 90%. This signals significant pressure on core business profitability—investors should closely watch any recovery.
• Cash Flow Plunge: Operating cash flow dropped by more than 90%, showing notable stress on working capital, possibly affecting dividends and expansion.
• Formulation Sales Growth: Formulation business performed strongly, with sales up 26.11% YoY, showing the effectiveness of the strategic shift.
• R&D Progress: Though R&D spending decreased, several products obtained registration certificates, including Ibuprofen sustained release capsules, Torasemide injection, Ibuprofen suspension, and Febuxostat tablets. New products may drive future revenue.
• Patent & International Certification: New patent filings and FDA cGMP certification boost technical barriers and global competitiveness.
• High-Tech Certification: Re-certification supports ongoing tax benefits.
• Project Progress: Ibuprofen API safety upgrade project is operational; international high-end formulation project construction underway, promising future capacity and market expansion.
• Dividend: Cash dividend maintained, showing commitment to shareholder returns.
• Stable Shareholding Structure: Controlling shareholders remain unchanged, but some shares are pledged; investors should watch for pledge risks.

Main Products & Market Advantages

• API Business: Core focus on non-steroidal anti-inflammatory APIs, with cardiovascular, oncology, and anticholinergic APIs as supplements. Products meet global pharmacopeia and GMP standards, registered in 80+ countries, supplying major pharma giants.
• Formulation Business: Uses self-produced APIs to develop antipyretic, cardiovascular, anti-infective formulations, with many products included in national health insurance and essential drug lists.
• CDMO Business: Offers end-to-end R&D and production services from pre-clinical to commercialization, forming leading contract development and manufacturing capabilities.
• Key Products: Ibuprofen, Dexibuprofen, Torasemide, Milrinone, Abiraterone Acetate, Fludarabine Phosphate, Granisetron Hydrochloride, Cladribine, Scopolamine Sulfate, Atropine Sulfate, etc. Formulations include Ibuprofen granules/sustained release capsules/suspension, Torasemide tablets, etc.
• New Drug Development: Several new drugs approved or progressing, including Ibuprofen sustained release capsules, Torasemide injection, Ibuprofen suspension, Febuxostat tablets, Arginine Ibuprofen API, and Metoclopramide API.

Financials & Shareholder Structure

• Asset Scale: Total assets RMB 2.49 billion, down 3.49% YoY.
• Net Assets: Shareholder equity RMB 2.31 billion, down 1.58% YoY.
• EPS: Basic EPS of RMB 0.08, sharply down YoY.
• Shareholder Structure: Shanghai Yongda Sheng Business Consulting holds 38.25%, actual controller’s family is united, some shares are pledged.
• Debt: No outstanding bonds.
• Quarterly Performance: Q4 saw net profit recovery; most profits were generated in Q4.

Investment Risks & Potential Impact

• Profit Volatility: Net profit and net profit excluding non-recurring items fell sharply—future performance uncertainty must be watched.
• Cash Flow Risk: Severe drop in operating cash flow—may affect dividends and project investments.
• Equity Pledge: Some key shareholders’ shares are pledged—watch for forced liquidation risk.
• New Product Launch: New drugs approved for market. If sales succeed, may drive revenue growth.
• International Expansion: CDMO and API internationalization progressing. Successful market expansion may boost valuation.
• Dividend: Cash dividend maintained, shows ability to support shareholder returns.
• High-Tech Certification: Supports tax incentives and policy benefits.

Conclusion & Outlook

Hubei Hengdi Pharmaceutical’s 2025 annual report shows the company is at a strategic turning point, with new product launches and international expansion underway. While profits and cash flow are under pressure, growth in the formulation business, international certification, patent development, and project progress open up future growth potential. New drug launches and international market expansion may drive performance rebound. Investors should closely watch operating recovery, innovation outcomes, cash flow trends, and equity pledge risks. Short-term sentiment may be affected by profit and cash flow declines, but long-term, successful formulation business and international breakthroughs could significantly lift valuation.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should consider their risk tolerance, monitor company disclosures and market changes, and make rational decisions.

View 亨迪药业 Historical chart here